Bolt Biotherapeutics (BOLT) Total Non-Current Liabilities (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Total Non-Current Liabilities of $28.0 million for Q1 2026, down 6.85% sequentially from $30.1 million in Q4 2025, and down 27.94% YoY from $38.9 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $28.0 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 27.94% year-over-year to $28.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.0 million (down 27.94% YoY) and the FY2025 annual result came in at $30.1 million, down 29.04% from the prior year.
- Total Non-Current Liabilities fell to $28.0 million in Q1 2026 per BOLT's latest filing, from $30.1 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $56.9 million in Q3 2022 and troughed at $28.0 million in Q1 2026.
- A 5-year average of $43.2 million and a median of $42.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 157.24% in 2022, then retreated 29.04% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $56.3 million in 2022, then dropped by 16.46% to $47.0 million in 2023, then decreased by 9.71% to $42.4 million in 2024, then declined by 29.04% to $30.1 million in 2025, then fell by 6.85% to $28.0 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $28.0 million, $30.1 million, and $32.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Bolt Biotherapeutics | 5.83 Mn | 5.83 Mn | - | 27.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.57 Mn |
| Mar 31, 2026 | 28.05 Mn |
| Dec 31, 2025 | 30.11 Mn |
| Sep 30, 2025 | 32.82 Mn |
| Jun 30, 2025 | 36.52 Mn |
| Mar 31, 2025 | 38.92 Mn |
| Dec 31, 2024 | 42.43 Mn |
| Sep 30, 2024 | 37.30 Mn |
| Jun 30, 2024 | 38.32 Mn |
| Mar 31, 2024 | 38.73 Mn |
| Dec 31, 2023 | 47.00 Mn |
| Sep 30, 2023 | 47.05 Mn |
| Jun 30, 2023 | 48.52 Mn |
| Mar 31, 2023 | 48.45 Mn |
| Dec 31, 2022 | 56.26 Mn |
| Sep 30, 2022 | 56.86 Mn |
| Jun 30, 2022 | 52.07 Mn |
| Mar 31, 2022 | 54.20 Mn |
| Dec 31, 2021 | 57.39 Mn |
| Sep 30, 2021 | 58.42 Mn |